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The role of non-steroidal anti-inflammatory drugs in inflammatory bowel disease is controversial, as they have been implicated
in disease aggravation. Different from other cyclooxygenase inhibitors, acetylsalicylic acid (ASA) enhances the formation of anti-
inflammatory and proresolution lipoxins derived from arachidonic acid as well as resolvins from omega-3 polyunsaturated fatty
acids such as docosahexaenoic acid (DHA). In this study, we examined the effect of ASA on murine dextran sodium sulfate colitis.
A mouse magnetic resonance imaging (MRI) protocol and post mortem assessment were used to assess disease severity, and
lipid metabolites were measured using liquid chromatography-coupled tandem mass spectrometry. Decreased colitis activity was
demonstrated by phenotype andMRI assessment inmice treatedwithASA, and confirmed in postmortem analysis. Analysis of lipid
mediators showed sustained formation of lipoxin A4 and an increase of DHA-derived 17-hydroxydocosahexaenoic acid (17-HDHA)
after treatment with ASA. Furthermore, in vitro experiments in RAW264.7 murine macrophages demonstrated significantly
increased phagocytosis activity after incubation with 17-HDHA, supporting its proresolution effect.These results show a protective
effect of ASA in a murine colitis model and could give a rationale for a careful reassessment of ASA therapy in patients with
inflammatory bowel disease and particularly ulcerative colitis, possibly combined with DHA supplementation.
1. Introduction
The inflammatory bowel diseases (IBDs) ulcerative colitis
(UC), confined to the colon, andCrohn’s disease (CD), affect-
ing the whole gastrointestinal tract, are chronic inflamma-
tory disorders with considerable morbidity and, particularly
for UC, mortality due to a high risk of colorectal cancer
development. Current therapy for IBD focuses on drugs
that inhibit inflammation [1–4]. Human data regarding the
potential benefits and risks of COX inhibition in patients with
IBD are conflicting [5–9]. This is also reflected in animal
studies examining COX inhibition in experimental colitis
models. While some recent studies found deleterious effects
in animals with DSS colitis associated with inhibition of COX
[10–13], others demonstrated a benefit of COX-2 inhibitor
treatment [14, 15].
Recently, newly discovered lipid mediators have been
implicated in the alleviation of colitis [16]. The lipoxins are
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lipid mediators originating from the omega-6 polyunsatu-
rated fatty acid (n-6 PUFA) arachidonic acid (AA) by enzy-
matic action of different lipoxygenases or by acetylated COX-
2 [17]. Studies have demonstrated potent anti-inflammatory
and inflammation dampening properties for lipoxins [18],
and stable analogues of lipoxins were shown to alleviate
experimental colitis [19, 20]. Similarly, protective lipid medi-
ators (so-called resolvins) can be formed from omega-3
polyunsaturated fatty acids (n-3 PUFAs) such as eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA). Our
previous work demonstrated formation of resolvins in mice
with increased omega-3 fatty acid tissue content in the
context of DSS colitis [21], and other studies have shown an
anti-inflammatory effect of several of these compounds in the
context of experimental colitis models [22–24].
In this study, we analyzed the effect of acetylsalicylic acid
(ASA) in chemically induced acute DSS colitis in mice. DSS
colitis is characterized by initial injury to the epithelial cells
followed by inflammation and has been shown to be a good
model to test therapeutics for human inflammatory bowel
disease [25]. Many studies have used this model in the past as
it is regarded as a good animal model of IBD, and particularly
UC, with a predominant site of inflammation in the distal
colon [26].
To evaluate disease activity in the different groups, we
extended our analysis beyond the conventional phenotype
and morphology markers and employed small animal MRI
technology. Noninvasive imaging in murine models of colitis
has been previously described using CT and MRI technolo-
gies [27–29]. For the study presented here, a modified pro-
tocol was devised in order to reliably measure and compare
colon wall thickness and hyperemia in different mice.
To assess possible mechanisms responsible for the
observed protection in ASA-treated mice, mass spectro-
metric measurements were then employed to determine
hydroxylated lipid metabolites and mediators derived from
AA (lipoxin A
4
and 15-epi-lipoxin A
4
) and from 17-hydroxy-
docosahex-aen-o-ic acid (DHA).
2. Materials and Methods
2.1. Induction of Colitis. Female C57BL/6mice were obtained
fromCharles River Laboratories (Wilmington,MA) and held
until the desired age (6 weeks) and body weight (19–21 g).
For testing of different treatment regimens, mice were
divided into 3 groups. One group received 3% DSS dissolved
in sterile drinking water and daily intraperitoneal (ip) injec-
tions of 0.5mg acetylsalicylic acid (ASA, Sigma-Aldrich, St.
Louis, MO) dissolved in 300 𝜇L of vehicle (3.33% EtOH in
0.9% NaCl) for 5 days (𝑛 = 5). Another group received 3%
DSS as well as ip injections of the vehicle alone for 5 days (𝑛 =
6). Finally, the last group received sterile drinking water and
ip injection of vehicle alone and served as a control (𝑛 = 3).
The first ip injection of ASA or vehicle was administered right
before the mice were switched to DSS-containing drinking
water. After 5 days, the DSS-containing water was replaced
with sterile drinking water.
2.2. Evaluation of Colitis Severity. Body weight measurement
(presented as percentage of body weight on day 0) as well as
evaluation of stool status was carried out daily. Stool samples
from individual mice were evaluated on a three-point scale
using a test for occult blood (Hemoccult, Beckman Coulter
Inc., Fullerton, CA) as well as macroscopic evaluation (0 =
no occult blood; 1 = test for occult blood slightly positive;
2 = test for occult blood strongly positive; and 3 = bloody
stool). On day 9, mice were sacrificed, colons were excised,
and length was measured. All samples were snap frozen in
liquid nitrogen and stored at −80∘C for further analysis.
2.3. Histological Evaluation. Frozen tissue sections from the
distal colon of all mice were mounted in OCT medium.
Sections were cut at 5𝜇m thickness and mounted on glass
slides. After air drying, sections were fixed in fixing medium
(70% ethanol, 4% formaldehyde, and 5% glacial acetic acid
in H
2
O), washed in ethanol (70%) and water, followed by
standard hematoxylin and eosin stain. Slides were evaluated
in a blinded manner and scored according to severity of
inflammation (0 = no inflammation, 1 = mild, 2 = moderate,
and 3 = severe), thickness of inflammatory involvement (0 =
no inflammation, 1 = mucosa, 2 = mucosa plus submucosa,
and 3 = transmural), character of epithelial damage (0 =
intact epithelium, 1 = disruption of architectural structure, 2
= erosion, and 3 = ulceration), and extent of lesions (0 = no
lesions, 1 = punctuate, 2 = multifocal, and 3 = diffuse). This
evaluation protocol is based on a previously described scoring
system for DSS colitis [30].
2.4. Magnetic Resonance Imaging (MRI). Mice were scanned
on day 3 and day 8 of the experimental protocol. MRI
assessment of colitis was performed using a Bruker 4.7T
Avance horizontal bore system (Bruker Avance, Karlsruhe,
Germany) equipped with a 200mm gradient set capable of
30G/cm gradient strength. During the MR scan, the mice
were mounted on a home-built nonmagnetic holding bar
equipped with a nose cone for anesthesia delivery and were
anaesthetized using 1.5%–2% (vol/vol) isoflurane (Baxter,
Deerfield, IL) in 1 L/min oxygen flow. The breathing rate of
the mice was monitored using a small animal monitoring
and gating system (Small Animal Instruments Inc., NY). The
isoflurane flowwas adjusted to achieve a breathing rate of 20–
30 breaths per minute during the scanning process. In order
to standardize the comparisons of wall thickness as well as
colon wall signal intensity between different animals, a non-
magnetic (plastic) tube (outer diameter 2.1mm) was placed
approximately 9mm into the rectum of the anaesthetized
mice (Figure 1(a)). For each mouse, 24 T2 weighted 2D axial
images were acquired to cover the colon using a fast spin
echo sequence with a repetition time (TR) of 2683ms, an
echo time (TE) of 12ms, a 128 × 128 matrix, and a 3.0 cm
× 3.0 cm field of view (FOV). The slice thickness was set
to 1mm, and the number of averages was 8. After image
acquisition, the plastic tube was removed, and the animals
were transferred to a heating pad until they were fully awake.
The images were analyzed using standard imaging software
(Adobe Photoshop, Adobe Systems, San Jose, CA).
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Figure 1: MRI analysis of colitis severity. (a) For MRI analysis of disease severity, a plastic tube with outer diameter of 2.1mm was carefully
placed approximately 9mm into the rectum of the anaesthetized mouse. (b) Analysis was performed by comparing wall thickness as well as
brightness between the different mice in three defined slices.
Colon wall thickness was then measured on the T2
weighted images from three slices of the distal colon with a
standardized distance of 3mm between slices (Figure 1(b)).
For each slice, three measurements were performed, and the
means for each animal were calculated. For signal intensity
analysis, a region of interest (ROI) was drawn within the
colon wall. A histogram tool was used to analyze the bright-
ness of the pixels within the ROI. This was repeated for the
same three slices that were used for the wall thickness mea-
surements.The pixel brightness means were then normalized
by comparisonwith the nearby fatty tissue around the ovaries
of the mice.
2.5. Lipid Metabolite Analysis. 30mg ground and frozen
colon tissue was mixed with 500𝜇L water and 500𝜇L
methanol, internal standard consisting of 10 ng LTB
4
-d
4
was
added, and the sample was then hydrolyzed with 300𝜇L
of 10M sodium hydroxide for 30 minutes at 60∘C. The
solution was neutralized with 60% acetic acid, and the pH
was adjusted to 6.0 with sodium acetate buffer. A solid phase
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extraction was performed as previously described [31]. For
elution, an n-hexane:ethyl acetate extractionmixture (25 : 75)
with 1% acetic acid was used. The eluate was evaporated
on a heating block at 40∘C under a stream of nitrogen
to obtain a solid residue. Residues were then dissolved
in 70𝜇L acetonitrile and measured using an Agilent 1200
HPLC system coupled to an Agilent 6410 Triple quad mass
spectrometer with an electrospray ionization source. Analysis
of lipid metabolites was performed with multiple reaction
monitoring in negative mode.
2.6. Phagocytosis Assay. RAW 264.7 cells were grown in
Dulbecco’smodified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum, 100U/mL penicillin, and
100U/mL streptomycin. All experiments were performed in
a humidified atmosphere under 5% CO
2
at 37∘C. Cells were
plated in 96-well plates at a density of 1 × 105 cells/well and
incubated overnight. To quantify phagocytosis, cells were
incubated with fluorescein-labelled bioparticles (Vybrant
Phagocytosis Assay, Invitrogen, Carlsbad, CA), diluted 1 : 2.
Uptake was measured after 4 h in a fluorescence plate reader,
essentially following the manufacturer’s protocol. To evaluate
the effect of 17-HDHA on phagocytosis, cells were pretreated
with 1𝜇M 17-HDHA for 2 h. Positive controls with equivalent
volumes of ethanol (vehicle) and negative controls were
performed in parallel.
2.7. Statistical Analysis. Statistical analysis was performed
with GraphPad Prism 3.02v Software (GraphPad, La Jolla,
CA). Comparison was made using the Mann-Whitney U test
or as indicated. All values are presented as the mean ± SEM.
Statistical significance was set at 𝑃 < 0.05.
3. Results
Induction of colitis resulted in marked changes in body
weight, appearance of fecal blood, and general status. Mice
treated with ASA showed significantly less body weight loss
(Figure 2(a)) as well as a recovery of body weight within 3
days after the end of DSS exposure, while untreated mice
exhibited only a stabilization of body weight after cessation
of DSS.
Colitis disease activity was evaluated by MRI on day 3
and day 8 of the treatment protocol. The MRI results show a
marked difference between the treated groups of mice with
less wall thickness and a significantly lower T2 weighted
signal intensity (brightness) in the mice treated with ASA, as
signs of a lower inflammatory infiltration (Figure 2(b)). Due
to technical limitations in the number of MRI scans we were
able to perform, only 3 animals per groupwere assayed,which
does not give enough values for statistical normality testing
using, for example, the Kolmogorov-Smirnov test. Applying
nonparametric Mann-Whitney U testing to these data led
to nonsignificant findings. However, when hypothesizing
normal distribution—and thus applying Student’s t-test—for
these data, the differences for thickness as well as brightness
were significant on day 3 and day 8 with 𝑃 < 0.01 when
comparing the ASA + DSS group versus DSS alone.
The results of the MRI and body weight analyses con-
firmed the decreased disease activity in the mice treated
with ASA. Furthermore, assessment of bloody stools in the
animals showed a trend towards more severe and prolonged
bleeding in the DSS group (Figure 2(c)). However, conclusive
statistical evaluation of these data could not be performed, as
it was not possible to do stool testing on every animal every
day of the experimental protocol.
The in vivo disease activity assessments were validated
in the postmortem analysis of the colons, with wall thick-
nesses similar to those observed in the MRI measure-
ments (Figure 3(a)) and significantly less colon shortening in
mice treated with ASA as compared to mice exposed only
to DSS (Figure 3(b)). Microscopic grading of the changes
in the colon revealed decreased inflammatory activity in
mice treated with ASA (summarized scores are shown in
Figure 3(c)). However, we were not able to document changes
in inflammatory activity biochemically, as serum TNF-𝛼
levels, measured by ELISA, were not significantly different
between the different treatment groups (data not shown).
As lipid mediators formation of AA-derived lipoxins
and n-3 PUFA-derived resolvins can be increased by ASA-
induced acetylation of the COX-2 enzyme [32], we assessed
several of these mediators and their precursors in the colons
of mice with DSS-induced colitis with and without treatment
with ASA. Due to the presence of AA and DHA but not
EPA in the colon tissue of the mice used in this study (data
not shown), we focused on the assessment of AA-derived
lipoxins and DHA-derived 17-hydroxydocosahexaenoic acid
(17-HDHA). LipoxinA
4
and 15-epi-lipoxinA
4
concentrations
were decreased in colon tissue frommice three days after DSS
exposure, but formation of 15-epi-lipoxinA
4
was significantly
higher in mice treated with ASA as compared to the DSS
alone treatment group (Figures 4(a) and 4(b)). Unexpectedly,
the DHA-metabolite 17-HDHA was significantly higher in
colon tissues from mice three days after DSS exposure
(Figure 4(c)) and was increased even more in tissue samples
from mice treated with ASA.
In order to further elucidate the mechanism by which
17-HDHAmight contribute to inflammation dampening and
resolution, the in vitro ability of 17-HDHA to increase phago-
cytosis was tested. In these experiments, an assay systemwith
fluorescently labeled E. coli K-12 bioparticles was used as a
tool to study overall phagocytotic activity of macrophages
[33, 34]. A significant (1.25-fold) increase in phagocytosis
activity after 1 𝜇M17-HDHApreincubation in the RAW264.7
murinemacrophage cell line was demonstrated (Figure 5(a)).
4. Discussion
The data presented here indicate that DSS-induced colon
inflammation can be alleviated by acetylsalicylic acid.
Although a number of previous studies have examined the
effectiveness of COX inhibitors in the context of DSS colitis,
the outcomes of these studies were inconsistent or conflicting
[10–15], and, to our knowledge, ASA was never used in
experimentalDSS colitis.Thismay be due to the fact that ASA
causes ulcerations, erosions, and gastrointestinal bleeding in
the stomach as well as the small bowel, and many clinicians
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Figure 2: In vivo assessment of colitis severity. (a) Body weight course in the different groups, 𝑛 = 3 for the control group, 𝑛 = 5 for the
ASA-group, and 𝑛 = 6 for the DSS group; ∗𝑃 < 0.05 versus DSS. (b) MRI-measured colon wall thickness and brightness on day 3 as well as
day 8 of the experimental protocol, 𝑛 = 3 for each treatment group. In dashed lines, the values of measurements in untreated control mice
are shown. (c) Bleeding score evaluation in animals treated with DSS or ASA + DSS. There was no bleeding in control animals (not shown).
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Figure 3: Postmortem assessment of colitis severity. (a) Hematoxylin and eosin stains of transmural colon walls. Representative images of
control tissue as compared to animals treated withDSS andASA+DSS. (b) Colon shortening as an indicator of disease severity was compared
between the different experimental groups, 𝑛 = 5 for the ASA-group and 𝑛 = 6 for the DSS group; ∗𝑃 = 0.044 versus DSS. (c) Histological
grading score, 𝑛 = 5 for the ASA-group and 𝑛 = 6 for the DSS group; ns𝑃 = 0.054 versus DSS. Untreated controls (not shown) reached a
maximum of 2 points in this score.
believe it therefore to be too GI toxic to be of any value in the
control of colonic inflammation.
At the same time, patients with IBD, and particularly UC,
remain at increased risk for colorectal cancer [35, 36]. Long-
term ASA treatment has been shown to be effective for colon
cancer prevention [37–40]. In patients with UC, although
data in this field is scarce, a similar risk reduction of colorectal
cancer could be shown [41], arguing for ASA use also in these
patients.
We set out to study the effect of ASA supplementation
on the course of DSS-induced colitis in mice, hypothesizing
an effect of aspirin treatment on the formation of hydroxy-
lated lipid mediators such as the lipoxins as well as DHA-
derived compounds.These were characterized as potent anti-
inflammatory compounds also in the context of DSS colitis in
previous studies [19, 23].
In our experiments, we aimed for an ASA dose compa-
rable to low-dose ASA administration in humans. Previously
published data on low-dose ASA administration inmice with
intestinal or other tumors used doses of 40mg/kg [42] and
50mg/kg [43]. High-dose ASA dosage was at 400mg/kg in
a previous tumor prevention study in mice [44]. Two studies
in intestinal tumor models used a dose of 25mg/kg [45, 46],
which the authors calculated to correspond to a dose of 80–
110mg/day in humans on a 2000 kcal diet following nutrient
density calculations [47], and we decided to use this dose in
our experiment to mimic low-dose ASA administration. A
limitation of the data presented here is that no experiments
with ASA only treatment were performed. However, the
previous study by Mahmoud et al. has established the safety
of long-term administration of ASA at a dose of 25mg/kg in
mice [45].
In the study presented here, we found significant changes
in the tissue concentrations of anti-inflammatory lipoxins,
with suppression of lipoxin A
4
and 15-epi-lipoxin A
4
in the
mice with DSS colitis. As compared to this, the lipoxin
levels in the ASA-treated animals were higher, which could
contribute to the protection fromcolitis seen in these animals.
In contrast, the amount of the DHA-derived 17-HDHA
increased in animals after DSS treatment and even more so
with concomitant ASA treatment. While higher levels of 17-
HDHAwere present in the colons frommice after DSS colitis
induction as compared to controls, the treatment with ASA
led to even higher 17-HDHA tissue concentrations.
17-HDHA is the precursor for the formation of anti-
inflammatory D resolvins, and several previous studies from
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Figure 4: Assessment of lipid mediators. Shown are the arachidonic acid-derived lipoxin A4 (a) and 15-epi-lipoxin A4 (b) with 𝑛 = 3 for the
control group, 𝑛 = 5 for both the DSS alone and the DSS plus ASA groups; ns𝑃 = 0.056 versus DSS (not significant); ∗𝑃 = 0.016 versus DSS.
(c) The levels of 17-HDHA, with 𝑛 = 3 for the control group, 𝑛 = 5 for both the DSS alone and the DSS plus ASA groups; ∗𝑃 = 0.036 versus
controls; ∗∗𝑃 = 0.008 versus DSS (b).
other groups have demonstrated biological effects of the
different stereoisomers of this compound, as summarized
in (Figure 5(b)). It was shown that TNF-𝛼 secretion from
murine macrophages can be suppressed by 17S-HDHA [48].
Furthermore, it has been demonstrated that 17S-HDHA is
a precursor of the D(S)-resolvins, which are potent anti-
inflammatory mediators [49–51]. Similarly, the 17-HDHA
epimer 17R-HDHA as well as the D(R)-resolvins were
recently shown to be anti-inflammatory in the context of
experimental colitis, peritonitis, and arthritis [23, 51, 52].
The liquid chromatograph tandem mass spectrometry
(LC-MS/MS) setup used in the study presented here was not
able to differentiate between the 17S- and 17R-HDHAepimers
and could not reliably identify resolvin D1 in tissue samples.
However, as both epimers of 17-HDHA are precursors of
anti-inflammatory D-resolvins, the increase in total 17(R/S)-
HDHA observed in this study is an indicator of significantly
increased formation of these anti-inflammatory lipid media-
tors derived from DHA.
Indeed, our in vitro results presented previously showed
a 17-HDHA-triggered decrease in TNF-𝛼 secretion [53].
Together with the increased phagocytosis activity by 17-
HDHA shown here (Figure 5), this indicates that a mix of
the 17R/S-HDHA epimers itself carries anti-inflammatory
activity. Data for lipoxin A4 [54, 55] and resolvin D1 [56] have
established the concept of increased phagocytosis as amarker
of inflammation dampening and resolution. Therefore, the
data shown here for 17-HDHA add to the hypothesis that
increasing the phagocytosis activity of macrophages is an
important effect of the hydroxylated anti-inflammatory and
proresolution lipid mediators derived from either AA or
DHA.
Concerning the anti-inflammatory effect of ASA, the
results presented here support additional anti-inflammatory
mechanisms of ASA as compared to the mere inhibition of
prostaglandin synthesis, by enhancing the formation of 17-
HDHA in murine colitis. Together with the established effect
of ASA in colon cancer prevention, the findings presented
here might thus be able to contribute to interest in a careful
reevaluation of ASA therapy in patients with UCwith its high
risk of colon cancer development, possibly in combination
with DHA supplementation.
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